FDA scientists warn against expanded peptide access as Kennedy reshapes advisory panel

Article excerpt

Federal health scientists are urging caution about expanding access to controversial peptide drugs, even as the U.S. Food and Drug Administration (FDA) reshapes the advisory panel that will consider whether to loosen those restrictions.